Vancomycin Taper to Prevent Recurrent Clostridioides Difficile

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2026
Indirect evidence from network meta-analyses of randomized controlled trials (RCTs) suggest that a pulse and taper (P-T) of vancomycin may be non-inferior to 10-days of fidaxomicin for the prevention of recurrent Clostridioides difficile infections (rCDI). The aim of this trial is: 1\) For first episodes and first recurrences of CDI, to test whether a vancomycin P-T is non-inferior to 10-days of fidaxomicin for the prevention of rCDI at 56 days
Epistemonikos ID: 224ef18b866b9acb497eee58330a2fe211a1a536
First added on: Jan 10, 2026